Q-omics provides the consensus-scored TTLL7 profile across patient tissues and cancer cell-line models. TTLL7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TTLL7 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, TTLL7 RNA expression shows 19,007 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where TTLL7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL7 survival associations across molecular data types. TTLL7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL7 RNA expression–survival associations across cancer types. High TTLL7 expression shows unfavorable associations in BLCA, LIHC, MESO and LGG, but favorable associations in SCLC and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TTLL7 RNA expression.
This table summarizes TTLL7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TTLL7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL7 shows lower tumor expression in THCA, KICH, LUSC, BLCA and LUAD and higher tumor expression in KIRC. The THCA box plot shows higher TTLL7 RNA expression in normal versus tumor tissue (log2 FC = −1.434, t-test p < 0.001).
This table shows molecular features associated with TTLL7 in patient tissues and cancer cell lines. In patient samples, TTLL7 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
